The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kornilova E.B.

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

Polyakova K.I.

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

Shkurko T.V.

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Pirogov Russian National Medical Research University, Ministry of Health of Russia, Moscow, Russia

Kniazev O.V.

GBUZ "Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr" Departamenta zdravookhraneniia Moskvy

Ermolaeva A.D.

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia;
Loginov Moscow Clinical Scientific and Practical Center of the Moscow Healthcare Department, Moscow, Russia ,Sechenov First Moscow State Medical University Ministry of Health of Russia, Moscow, Russia

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Ermolaeva T.N.

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

Fisun A.G.

Research Institute for Health Care Organization and Medical Management of the Moscow Healthcare Department, Moscow, Russia

Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow

Authors:

Kornilova E.B., Polyakova K.I., Shkurko T.V., Kniazev O.V., Ermolaeva A.D., Davydovskaya M.V., Ermolaeva T.N., Fisun A.G.

More about the authors

Read: 4870 times


To cite this article:

Kornilova EB, Polyakova KI, Shkurko TV, et al. . Economic rationale for administration of vedolizumab in patients with inflammatory bowel disease in Moscow. Russian Journal of Evidence-Based Gastroenterology. 2019;8(3):55‑70. (In Russ.)
https://doi.org/10.17116/dokgastro2019803155

Recommended articles:
Insu­lin resi­stance as a cardiovascular risk factor in patients with ulce­rative coli­tis. Russian Journal of Evidence-Based Gastroenterology. 2024;(3):42-49
Celiac disease in men aged 18—27: new data on prevalence and clinical features. Russian Journal of Evidence-Based Gastroenterology. 2025;(1):55-62
Differential diagnosis of anemia in ulce­rative coli­tis: a clinical case. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):115-120
Clinical features of vene­real lymphogranuloma course. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(3):313-320
Modern treatment of perianal fistulas following Crohn’s disease. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(2):49-56
Influence of diagnostic period on the outcomes in patients with Crohn’s disease. Piro­gov Russian Journal of Surgery. 2024;(7):36-44

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.